Company news: Eli Lilly and Boehringer Ingelheim

Share this article:
Eli Lilly will pay Boehringer Ingelheim $387.4 million as part of a deal to jointly develop and commercialize several diabetes pipeline agents. Products covered under the pact include two oral agents from BI—DPP-4 inhibitor linagliptin, filed with the FDA, and SGLT-2 inhibitor BI10773, in Phase III—and two basal insulin analogues from Lilly which will enter Phase III this year, plus an option on Lilly's anti-TGF-beta monoclonal antibody. The firms will split revenues from any approved drugs, and the deal includes milestone payments -- up to $1 million for Lilly and up to  $807 million for BI. “This deal should inject some life into [Lilly's] diabetes franchise, which has been losing share,” wrote Credit-Suisse analyst Catherine Arnold in an investor note today.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.